← back to search

John W. Ostrominski

Harvard University · US
Area of research
Cardiology and Cardiovascular Medicine · Endocrinology, Diabetes and Metabolism
Research interest
Research interests include Heart Failure Treatment and Management, Diabetes Treatment and Management, Cardiovascular Function and Risk Factors, and Hormonal Regulation and Hypertension.
h-index
18
citations
2,176
works
152
NIH funding
primary concept
Medicine
email

Recent publications

Adiposity-Related Anthropometrics and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
Journal of the American College of Cardiology 2025cited by 18position: firstdoi
Anthropometric Measures, Cardiovascular Outcomes, and Treatment Effects of Finerenone in Cardiovascular-Kidney-Metabolic Disease
Journal of the American College of Cardiology 2025cited by 9position: firstdoi
State-Level Prevalence of Cardiovascular-Kidney-Metabolic Syndrome Stages in the United States, 2011 to 2023
JACC Advances 2025cited by 8position: lastdoi
Finerenone and NYHA Functional Class in Heart Failure
JACC Heart Failure 2025cited by 6position: firstdoi
Prevalence of Cardiovascular-Kidney-Metabolic Syndrome Stages in US Adults, 2011-2020
JAMA 2024cited by 380position: middledoi
Baseline Characteristics of Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction: The FINEARTS-HF Trial
European Journal of Heart Failure 2024cited by 60position: middledoi
Qualitative evaluation of artificial intelligence-generated weight management diet plans
Frontiers in Nutrition 2024cited by 38position: middledoi
Cardiovascular-Kidney-Metabolic Overlap in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
Journal of the American College of Cardiology 2024cited by 35position: firstdoi
Abstract 4147845: Valsartan and Cardiac Remodeling in Early-Stage Hypertrophic Cardiomyopathy: The VANISH Trial Cardiac Magnetic Resonance Substudy
Circulation 2024cited by 0position: firstdoi
Prevalence and Overlap of Cardiac, Renal, and Metabolic Conditions in US Adults, 1999-2020
JAMA Cardiology 2023cited by 238position: firstdoi
Cardio-Renal-Metabolic Overlap, Outcomes, and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
JACC Heart Failure 2023cited by 38position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Muthiah Vaduganathan · Harvard University7 papers (2023–2025)Brian Claggett · Harvard University6 papers (2023–2025)John J.V. McMurray · University of Glasgow5 papers (2023–2025)Pardeep S. Jhund · Harvard University5 papers (2023–2025)Faı̈ez Zannad · Université de Caen Normandie4 papers (2024–2025)Scott D. Solomon · Harvard University4 papers (2023–2025)Akshay S. Desai · Brigham and Women's Hospital4 papers (2023–2025)James Lay‐Flurrie · Brigham and Women's Hospital3 papers (2024–2025)Carolyn S.P. Lam · Duke-NUS Medical School3 papers (2023–2025)Sanjiv J. Shah · Akron General Medical Center3 papers (2023–2025)Marc A. Pfeffer · Harvard University2 papers (2024–2025)Katja Rohwedder · Harvard University2 papers (2025–2025)Bertram Pitt · Bayer (Germany)2 papers (2024–2025)Michael R. Zile · Texas A&M University System2 papers (2024–2025)Mikhail Kosiborod · Nagoya University2 papers (2023–2023)Michele Senni · Ospedale Papa Giovanni XXIII2 papers (2025–2025)Zi Michael Miao · Harvard University2 papers (2023–2024)Inder S. Anand · University of Minnesota2 papers (2024–2025)Thomas M. O’Connell · Indiana University School of Medicine1 papers (2023–2023)Javed Butler · Jackson College1 papers (2023–2023)